Page 1 Presents an in-depth market report on the following companies: Cyberonics Inc. (NASDAQ:CYBX), Medtronic, Inc. (NYSE:MDT), Edwards Lifesciences Corp (NYSE:EW)

Cyberonics, Inc. Profile: Cyberonics, Inc., a neuromodulation company, engages in the design, development, manufacture, sale, and marketing of implantable medical devices that provide vagus nerve stimulation (VNS) therapy for the treatment of refractory epilepsy and treatment-resistant depression. Its VNS therapy system consists of a pulse generator to provide the stimulation to the vagus nerve; a bipolar lead; a tunneling tool to assist with implantation surgery; a programming wand and software for setting the stimulation parameters particular to the patient; instruction manuals; and magnets to suspend or induce stimulation manually. The company sells its products for refractory epilepsy through direct sales and marketing forces in Austria, Belgium, Denmark, France, Germany, Ireland, Luxemburg, the Netherlands, Norway, Spain, Sweden, Switzerland, and the United Kingdom, as well as through distribution agreements with independent distributors of various territories, including Canada, Mexico, Australia, parts of Central and South America, China, Japan, and other parts of Asia, the Middle East, and other areas of Europe. Cyberonics, Inc. was founded in 1987 and is headquartered in Houston, Texas. Trading Activity: Today CYBX traded 862,393 shares on a bullish uptick closing the day at $32.56 up 8.86 % (+2.65/share). The average daily volume for CYBX is 172,692. CYBX has a 52 week range of between $16.55 and $32.65. CYBX closed very close to their 52 week high today on around 7 times their average volume. Technical Analysis: CYBX is showing pretty strong support all the way up to $29.86. The EMA is VERY BULLISH Across the board, and the MACD is neutral short term, bullish intermediate, and neutral long term. Recent candlestick analysis is VERY BULLISH showing a Bullish Engulfing on December 14th, 2010.


Medtronic, Inc. Profile: Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. The company’s Cardiac Rhythm Disease Management segment offers products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable cardioverter-defibrillators, cardiac resynchronization therapy devices, and cardiac pacemakers; AF products; diagnostics and monitoring devices; and patient management tools. Its Spinal segment provides medical devices and implants used in the treatment of the spine and the musculoskeletal system, such as thoracolumbar, cervical, and biologics products; and minimal access spinal technologies platform that facilitates spinal surgeries. Medtronic’s CardioVascular segment offers percutaneous coronary and peripheral vascular interventions; endovascular stent

grafts; arrested heart surgery and beating heart surgery equipment; surgical ablations; and surgical heart and transcatheter heart valves. The company’s Neuromodulation segment provides neurostimulators for chronic pain; implantable drug delivery and deep brain stimulation systems; and urology and gastroenterology devices. Its Diabetes segment offers integrated diabetes management solutions; professional CGM; carelink therapy management software; and blood glucose meters. The company’s Surgical Technologies segment develops, manufactures, and markets products and therapies to treat diseases and conditions of the ear, nose, and throat, as well as certain neurological disorders; and image-guided surgery and intra-operative imaging systems that facilitate surgical planning during surgeries. Its Physio-Control segment offers external defibrillators, including manual defibrillator/monitors used by hospitals and emergency response personnel; and automated external defibrillators used in commercial and public settings for the treatment of sudden cardiac arrest. Medtronic, Inc. was founded in 1949 and is headquartered in Minneapolis, Minnesota. Trading Activity: Today MDT traded 5,029,653 shares on a bit of a bearish downtick closing the day at $35.99 down 0.42 % (-0.15/share). The average daily volume for MDT is 6,996,510. MDT has a 52 week range of between $30.80 and $46.66. MDT closed very on exactly in the middle of their 52 week range on lighter than usually volume. Technical Analysis: MDT is showing minor resistance up to the $38.12 range, with support up to $35.97. The EMA is VERY BULLISH Across the board, and the MACD is VERY BULLISH short term, VERY BULLISH intermediate, and neutral long term. The RSI indicator is Bullish Intermediate. The TDD indicator is also Bullish intermediate, while the Fibs indicator is bullish short term, bearish intermediate, and bullish long term. The trends for MDT are NEUTRAL across the board. Recent candlestick analysis is VERY BULLISH showing a Homing Pigeon on December 14th, 2010. CHART:

Edwards Lifesciences Corp. Profile: Edwards Lifesciences Corporation provides products and technologies designed to treat advanced cardiovascular diseases. It offers products and technologies for heart valve therapy, critical care, cardiac surgery systems, and vascular diseases. The company provides tissue heart valves, such as pericardial and porcine valves, as well as repair products, including annuloplasty rings and systems used to replace or repair a patient's diseased or defective heart valve. It also offers hemodynamic monitoring equipment that is used to measure a patient's heart function in surgical and intensive care settings; and disposable pressure transducers. In addition, the company provides cardiac surgery systems products, including cannulae, intra-aortic filtration system, and other disposable products used during cardiopulmonary bypass procedures; and vascular products that comprise balloon-tipped and catheter-based embolectomy products, surgical clips, and clamps to treat endolumenal occlusive disease.

Edwards Lifesciences Corporation distributes its products through a direct sales force and independent distributors worldwide. It has a collaboration agreement with DexCom, Inc. to develop products for monitoring blood glucose levels in patients hospitalized for various conditions. The company was founded in 1999 and is headquartered in Irvine, California. Edwards Lifesciences Corporation operates independently of Baxter International Inc., as of March 31, 2000. Trading Activity: Today EW traded 1,807,281 shares on a bullish uptick closing the day at $81.26 up 3.98% (+3.11/share). The average daily volume for EW is 634,964. EW has a 52 week range of between $41.81 and $81.59. EW closed very close to their 52 week high today on around 3 times their average volume. Technical Analysis: EW is showing support all the way up to $76.41. The EMA is VERY BULLISH Across the board, and the MACD is VERY BULLISH short term, bearish intermediate, and very bearish long term. Recent candlestick analysis on EW is neutral. Chart:

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS. We are not registered as a securities broker-dealer or an investment advisor either within the U.S. Securities and Exchange Commission (the “SEC�) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them. Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research. Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment adviser or licensed stock broker before investing. This website is a service of Seo Freisin, Inc., a financial public relations firm that has

been compensated by the companies profiled. All direct and third party compensation received has been disclosed on both, this newsletter, and on our website in accordance with section 17(b) of the Securities Act of 1933. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. Seo Freisin, Inc., and/or its affiliates will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitues a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. Information contained in our report will contain “forward looking statements” as defined under section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance asto the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and thereforecannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be

reliable. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in this report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

Healthcare Stock Focus Report